NeRRe Therapeutics
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Phone Number
+44 1438906960Website
www.nerretherapeutics.comRevenue
$5.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About NeRRe Therapeutics
NeRRe Therapeutics is a UK-based clinical-stage company focused on developing orvepitant, a neurokinin-1 receptor antagonist, as a breakthrough treatment for cough hypersensitivity disorders, particularly in patients with idiopathic pulmonary fibrosis (IPF). The company aims to address the debilitating and persistent cough associated with this rare and terminal lung disease, for which there are currently no approved treatments. Founded in 2012 as a spin-out from GSK, NeRRe is backed by prominent life sciences investors and is led by an experienced management team. The company is committed to advancing its lead clinical asset, orvepitant, through ongoing preclinical and clinical development.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NeRRe Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on NeRRe Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once NeRRe Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if NeRRe Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if NeRRe Therapeutics had a recent Job posting/layoffs
NeRRe Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if NeRRe Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at NeRRe Therapeutics
Product Launch: Get notified when NeRRe Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined NeRRe Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to NeRRe Therapeutics
Compare insights from companies similar to NeRRe Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
NeRRe Therapeutics
$5.8M
11-50
Private
$36.3M
2012
N/A
Company Profile Activity
Activity Insights
NeRRe Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NeRRe Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NeRRe Therapeutics.
NeRRe Therapeutics financials insights
Gather financial insights about NeRRe Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Series A
$8.1M
2017
Series B
$28.2M
NeRRe Therapeutics Tech Stack
A closer look at the technologies used by NeRRe Therapeutics
See more technologies
NeRRe Therapeutics News & Media
Global Pruritus Drug Market Projected to Show Strong Growth by 2026 : Cara Therapeutics, Enteris BioPharma, NeRRe Therapeutics, Menlo Therapeutics, XBiotech, Ipsen Pharm
Pune, India -- (SBWIRE) -- 02/21/2020 -- Read the full press release at http://www.sbwire.com/press-releases/global-pruritus-drug-market-projected-to-show-strong-growth-by-2026-cara-therapeutics-enteris-biopharma-nerre-therapeutics-menlo-therapeutics-xbiotech-ipsen-pharm-1278141.htmNeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NeRRe Therapeutics
Sign Up For FreeTo access detailed company insights
NeRRe Therapeutics is a UK-based clinical-stage company focused on developing orvepitant, a neurokinin-1 receptor antagonist, as a breakthrough treatment for cough hypersensitivity disorders, particularly in patients with idiopathic pulmonary fibrosis (IPF). The company aims to address the debilitating and persistent cough associated with this rare... Read More
